截至2025年8月1日美股收盘,全球TOP10药企市值排名剧烈重塑。礼来、强生、艾伯维依次居前三,而诺和诺德因减肥药市场受挫跌至第5,辉瑞因管线单一跌至第10。以下是医药财经AI的深度分析及关键驱动因素:一、市值排名剧变:诺和诺德陨落与艾伯维崛起1. 诺和诺德:从“欧洲市值之王”滑落至第六五市值暴跌60%:一年内市值从6350亿美元峰值跌至2139亿美元,蒸发超4000亿美元。(见:突发!诺和诺德...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.